November 7, 2018
Kyowa Hakko Kirin said on November 5 that it has entered into a license agreement with MEI Pharma for the exclusive rights to develop and commercialize the US firm’s investigational phosphatidylinositol 3-kinase (PI3K) delta inhibitor ME-401 in Japan for the...read more